Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.

ABSTRACT:

Background

Both dabrafenib and trametinib (D + T) and anti-PD(L)1s have been shown to improve recurrence-free survival (RFS) in patients with stage III or resected stage IV BRAF-mutant melanoma. However, no randomized controlled trials (RCTs) have directly compared them in the adjuvant setting, creating uncertainties about the optimal approach. This systematic review and meta-analysis address this knowledge gap.

Methods

A comprehensive search of PubMed, Embase, and Scopus was conducted to identify studies comparing D + T with anti-PD(L)1 therapies. Studies with overlapping populations were excluded. Statistical analyses employed a random-effects model, with heterogeneity assessed via I 2 statistics. This study was registered with PROSPERO (CRD42024553421).

Results

Eig

SUBMITTER: Araujo DV 

PROVIDER: S-EPMC12449075 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature